ARCHIVES

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

This article is from The Cancer Letter archive.

Vol. 31 No. 22 | June 3, 2005

Download PDF Visit The Full Archive

Related Articles

Navelbine+Herceptin: 78% Response In Breast Cancer

November 29, 2002

NCI Programs: NCI To Study Colorectal Cancer Screening Practices

September 17, 1999

Schweiker Approves Chabner Appointment

September 10, 1982

FDA Nearly Wrecks NCI Drug Distribution Program, Finally Agrees To New Guidelines

January 30, 1976

Univ. Of Washington, Fox Chase, ICC Win CCRU, CCSP Awards

July 8, 1983

Rituximab and Fludarabine Combination Produces Long-Term Remissions in CLL

March 25, 2011